Page last updated: 2024-09-04

bdp 12 and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

bdp 12 has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 2 studies

Compound Research Comparison

Studies (bdp 12)	Trials (bdp 12)	Recent Studies (post-2010) (bdp 12)	Studies (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)	Trials (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)	Recent Studies (post-2010) (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
62	7	14	3,859	8	1,052

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Blanchet, PJ; Chase, TN; Konitsiotis, S; Lamers, E; Verhagen, L	1
Baumbarger, P; Bleakman, D; Gates, M; Hicks, CA; Lodge, D; Murray, TK; Nisenbaum, ES; O'Neill, MJ; Ogden, AM; Robinson, CS; Siuda, E; Skolnick, P; Vandergriff, JL; Ward, MA; Whalley, K; Zimmerman, DM	1

Other Studies

2 other study(ies) available for bdp 12 and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Article	Year
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology, 2000, Apr-25, Volume: 54, Issue:8 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzodiazepines; Dioxoles; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Parkinson Disease, Secondary; Piperidines; Receptors, AMPA; Severity of Illness Index	2000
LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease. The Journal of pharmacology and experimental therapeutics, 2003, Volume: 306, Issue:2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amides; Animals; Biphenyl Compounds; Cells, Cultured; Corpus Striatum; Dioxoles; Disease Models, Animal; Excitatory Amino Acid Agonists; GAP-43 Protein; Hippocampus; Humans; Male; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Piperidines; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Glutamate; Substantia Nigra	2003

Article

Year

AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys.

Neurology, 2000, Apr-25, Volume: 54, Issue:8

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzodiazepines; Dioxoles; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Parkinson Disease, Secondary; Piperidines; Receptors, AMPA; Severity of Illness Index

2000

LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.

The Journal of pharmacology and experimental therapeutics, 2003, Volume: 306, Issue:2

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amides; Animals; Biphenyl Compounds; Cells, Cultured; Corpus Striatum; Dioxoles; Disease Models, Animal; Excitatory Amino Acid Agonists; GAP-43 Protein; Hippocampus; Humans; Male; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Piperidines; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Glutamate; Substantia Nigra

2003